Tim Lewis, EVP, Strategic Development, Oncology and Precision Medicine; Vanitha Sankaran, SVP, Medical Strategy; Sarah Henry, Director, Medical Strategy; and Jordan Schell, Principal, EVERSANA® MANAGEMENT CONSULTING
At this year’s ASCO Annual Meeting, the future of oncology came into sharper focus — and EVERSANA was at the center of the conversation. From the expanding role of AI to the evolving biomarker landscape, our experts shared insights that are shaping the future of cancer care.
As featured in pharmaphorum, our team explored how “AI is no longer a buzzword — it’s a clinical imperative,” and how the convergence of data, technology, and patient-centered strategy is redefining what’s possible in oncology.
“We’re not just talking about the future — we’re building it. AI is helping us decode complexity, personalize care, and accelerate access to innovation.” — Tim Lewis, EVP of Strategic Development, Oncology and Precision Medicine at EVERSANA INTOUCH®
At EVERSANA INTOUCH, we understand that oncology is the most complex and rapidly evolving therapeutic area—and we’re built for it. As a leader in oncology marketing with over 23 years of experience across 140+ brands, we offer innovative, data-driven solutions that go beyond traditional approaches.
By leveraging Artful Ingenuity, the fusion technology, human ingenuity, and innovation, EVERSANA INTOUCH is the only global agency network connected to an end-to-end commercialization platform that powers long-term success in oncology.
Do you have pressing questions about oncology commercialization? Reach out for expert insights and solutions that will drive your brand’s success.
Hear from members of EVERSANA’s Oncology Center of Excellence, as they expand upon trends and insights from ASCO 2025 in this pharmaphorum interview.